Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) is now available.
Nanjing Leads Biolabs Co., Ltd. announced that five of its research abstracts, covering two innovative drugs, have been accepted for presentation at the 67th Annual Meeting of the American Society of Hematology. This inclusion highlights the company’s strong recognition in the international academic community for its scientific and innovative capabilities, potentially enhancing its industry positioning and stakeholder confidence.
The most recent analyst rating on (HK:9887) stock is a Buy with a HK$80.27 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.
More about Nanjing Leads Biolabs Co., Ltd. Class H
Nanjing Leads Biolabs Co., Ltd. is a joint stock company based in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on innovative drug research and development, showcasing its work on international platforms such as the American Society of Hematology and the American Society of Clinical Oncology.
Average Trading Volume: 1,836,351
For a thorough assessment of 9887 stock, go to TipRanks’ Stock Analysis page.